Sign In
Buy ARQT
$21.35
+0.560 (+2.69%)
At Close: Jun 03, 2026
Arcutis Biotherapeutics, Inc. (ARQT) Hit a 52 Week High, Can the Run Continue?
10:16am, Wednesday, 01'st Oct 2025
Arcutis Biotherapeutics (ARQT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Arcutis Biotherapeutics to Host Virtual Investor Day and Report Third Quarter 2025 Financial Results on October 28, 2025
04:00pm, Monday, 29'th Sep 2025
WESTLAKE VILLAGE, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on immuno-dermatology, today announced t
Biotech Leader Arcutis Is Breaking Out, Up Nearly 36% In 2025
11:33am, Monday, 29'th Sep 2025
Biotech leader Arcutis stock is breaking out past its latest buy point. Shares are up nearly 36% in 2025.
Are Medical Stocks Lagging Arcutis Biotherapeutics (ARQT) This Year?
10:41am, Monday, 29'th Sep 2025
Here is how Arcutis Biotherapeutics, Inc. (ARQT) and Cardinal Health (CAH) have performed compared to their sector so far this year.
Here's Why Arcutis Biotherapeutics, Inc. (ARQT) is a Great Momentum Stock to Buy
01:01pm, Thursday, 25'th Sep 2025
Does Arcutis Biotherapeutics, Inc. (ARQT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Arcutis To Present Multiple New ZORYVE® (roflumilast) Data Analyses at European Academy of Dermatology and Venereology Congress
04:00am, Wednesday, 17'th Sep 2025
New analysis of ZORYVE foam 0.3% demonstrates reduction in signs and symptoms of seborrheic dermatitis in individuals with diverse skin types New data show improved quality of life and decreased impac
Allure Magazine Honors Arcutis' ZORYVE® (roflumilast) with Prestigious Best of Beauty Breakthrough Award
09:00am, Tuesday, 16'th Sep 2025
First FDA-approved medication for atopic dermatitis (eczema), plaque psoriasis, and seborrheic dermatitis to win prominent “Breakthrough Award” ZORYVE is the number one prescribed branded topical
Arcutis Biotherapeutics, Inc. (ARQT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
06:37pm, Tuesday, 09'th Sep 2025
Arcutis Biotherapeutics, Inc. (ARQT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:00pm, Friday, 05'th Sep 2025
WESTLAKE VILLAGE, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations i
Arcutis Biotherapeutics, Inc. (ARQT) Presents At Citi's Biopharma Back To School Conference Transcript
03:08pm, Wednesday, 03'rd Sep 2025
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT ) Citi's Biopharma Back to School Conference September 3, 2025 9:45 AM EDT Company Participants Todd Watanabe - President, CEO & Director Latha Vairavan - Ch
If approved, ZORYVE cream would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children as young as 2, offering patients and caregivers an important alternative to topi
Does Arcutis Biotherapeutics (ARQT) Have the Potential to Rally 45.81% as Wall Street Analysts Expect?
10:56am, Monday, 01'st Sep 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 45.8% in Arcutis Biotherapeutics (ARQT). While the effectiveness of this highly sought-after metric is question
Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year?
10:41am, Wednesday, 27'th Aug 2025
Here is how Arcutis Biotherapeutics, Inc. (ARQT) and Foghorn Therapeutics Inc. (FHTX) have performed compared to their sector so far this year.
3 Biotech Catalysts Present Major Opportunity
06:33pm, Monday, 25'th Aug 2025
For biotech firms, a bit of positive news—a key result from clinical trials or new drug discovery, say—can be the difference between a major rally based on a path toward sustained profitability an
Arcutis: ZORYVE's Multi-Indication Momentum And Margin Expansion Justify A Bullish Re-Rate
03:37am, Saturday, 23'rd Aug 2025
Upgrading ARQT to buy due to explosive revenue growth, improving margins, and strong ZORYVE market adoption across multiple indications. ZORYVE now commands ~41% of non-steroidal topical psoriasis pre
